Well designed disease progression models can be valuable tools to help with drug development. The authors of this article have used these models to construct trial simulations that allowed for the optimization of trial designs, review of innovative trial design features and operating characteristics-including adaptive designs, and the investigation of novel analysis methodologies. This paper presents a disease progression model for RA based on a number of biologic agents that are used with a background therapy of methotrexate (MTX).

Read Article